Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Palatin Technologies Inc.

Start price
Target price
Perf. (%)
€3.44
20.01.24
€1.00
20.01.25
3.49%
03.02.24

High valuation
Bad rating
Little Investments for future growth
ROE lower than 10% per year
Gevo Inc.

Start price
Target price
Perf. (%)
€0.80
19.01.24
-
19.02.24
-1.13%
22.01.24

Risky Investment
buy
Adicet Bio Inc.

Start price
Target price
Perf. (%)
€2.25
18.01.24
-
18.01.25
2.18%
21.01.24

Could be worthwhile Investment >10% per year
Western Uranium Corp

Start price
Target price
Perf. (%)
€1.66
18.01.24
-
18.01.25
-15.36%
20.02.24

Could be very worthwhile Investment >20% year
buy
Leap Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.04
17.01.24
-
17.01.25
0.00%
21.01.24

Could be worthwhile Investment >10% per year
buy
AFC Energy plc

Start price
Target price
Perf. (%)
€0.21
15.01.24
€0.35
28.03.24
5.66%
28.03.24

Could be very worthwhile Investment >20% year
Market Leader or Top 3
Small cyclical dependencies
Well known brand
HelloFresh SE

Start price
Target price
Perf. (%)
€13.36
10.01.24
€15.00
10.01.25
-6.18%
15.01.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
buy
Leap Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.70
08.01.24
-
08.01.25
-17.84%
21.01.24

Could be worthwhile Investment >10% per year
buy
PDS Biotechnology Corp.

Start price
Target price
Perf. (%)
€4.62
07.01.24
-
07.01.25
-11.80%
20.01.24

Could be worthwhile Investment >10% per year
Gevo Inc.

Start price
Target price
Perf. (%)
€1.01
07.01.24
-
07.01.25
-20.87%
19.01.24

Risky Investment
buy
Db X-trackers S&p 500 2x Inverse Daily Ucits Etf

Start price
Target price
Perf. (%)
€0.34
06.01.24
-
06.01.25
-9.81%
15.02.24

Minim Inc.

Start price
Target price
Perf. (%)
€4.42
04.01.24
-
04.01.25
-23.53%
06.01.24

Risky Investment
buy
Cellectar BioSciences Inc.

Start price
Target price
Perf. (%)
€2.74
03.01.24
-
03.01.25
-3.65%
06.01.24

Risky Investment
buy
Crossject S.A.

Start price
Target price
Perf. (%)
€4.89
30.12.23
€5.50
30.12.24
-22.39%
10.02.24

Could be worthwhile Investment >10% per year
buy
TOP Ships Inc.

Start price
Target price
Perf. (%)
€0.56
29.12.23
€30.00
-
07.02.24

Could be very worthwhile Investment >20% year
buy
Leap Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.54
27.12.23
-
27.12.24
4.52%
07.01.24

Could be worthwhile Investment >10% per year
buy
Adicet Bio Inc.

Start price
Target price
Perf. (%)
€1.44
27.12.23
-
27.12.24
57.71%
07.01.24

Could be very worthwhile Investment >20% year
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.06
26.12.23
-
26.12.24
-8.96%
11.01.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
AC Immune Ltd

Start price
Target price
Perf. (%)
€4.16
26.12.23
-
26.12.24
-8.05%
19.01.24

Could be worthwhile Investment >10% per year
Bettermoo(d) Food Corporation

Start price
Target price
Perf. (%)
€1.00
26.12.23
-
26.12.24
13.00%
19.01.24

Probably not worthwhile Investment
buy
Ebang International Holdings Ltd.

Start price
Target price
Perf. (%)
€11.80
21.12.23
-
21.12.24
-9.32%
15.02.24

buy
HelloFresh SE

Start price
Target price
Perf. (%)
€14.32
19.12.23
€15.00
19.12.24
-6.67%
10.01.24

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
buy
Sino AG

Start price
Target price
Perf. (%)
€28.40
16.12.23
-
16.12.24
35.21%
18.03.24

buy
Altimmune

Start price
Target price
Perf. (%)
€5.09
12.12.23
-
12.12.24
30.56%
13.05.24

Could be worthwhile Investment >10% per year
buy
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€13.80
10.12.23
€40.00
10.12.24
-19.13%
26.03.24

Could be very worthwhile Investment >20% year
Rising EBIT margin expected
High Investments for future growth
Very valuable balance sheet